Trials / Recruiting
RecruitingNCT06190639
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive Esophageal Squamous Cell Carcinoma After Radical Surgery Without Neoadjuvant Therapy
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of sintilimab as adjuvant therapy in node-positive esophageal squamous cell carcinoma after radical surgery without neoadjuvant therapy. The main question it aims to answer is: • Efficacy of sintilimab as adjuvant therapy Participants will receive sintilimab 200 mg once on day 1, every 21 days(Q3W).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sintilimab | 200 mg once on day 1, every 21 days |
Timeline
- Start date
- 2023-10-25
- Primary completion
- 2025-12-31
- Completion
- 2027-12-31
- First posted
- 2024-01-05
- Last updated
- 2024-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06190639. Inclusion in this directory is not an endorsement.